Johnston, Jamie R.
Adler, Eric D.
Funding for this research was provided by:
National Institutes of Health (R01HL155281)
California Institute for Regenerative Medicine
Article History
Accepted: 2 July 2024
First Online: 7 August 2024
Declarations
:
: Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.